PetMed Express (PETS) Projected to Announce Quarterly Earnings on Tuesday

PetMed Express (NASDAQ:PETS) is anticipated to announce its Q2 2027 resultson Tuesday, October 13th. Analysts expect PetMed Express to post earnings of ($0.11) per share and revenue of $62.00 million for the quarter. Individuals can check the company’s upcoming Q2 2027 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 4:00 PM ET.

PetMed Express (NASDAQ:PETS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.40). PetMed Express had a negative return on equity of 91.69% and a negative net margin of 17.34%. The business had revenue of $41.02 million for the quarter, compared to the consensus estimate of $71.00 million. On average, analysts expect PetMed Express to post ($0.50) EPS for the current fiscal year and ($0.35) EPS for the next fiscal year.

PetMed Express Price Performance

PetMed Express stock opened at $1.28 on Friday. The company has a market cap of $27.86 million, a price-to-earnings ratio of -0.93 and a beta of 0.83. The firm has a 50-day moving average of $1.70 and a 200-day moving average of $1.95. PetMed Express has a one year low of $1.26 and a one year high of $4.10.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Zacks Research downgraded PetMed Express from a “hold” rating to a “strong sell” rating in a research note on Friday, September 25th. Wall Street Zen downgraded PetMed Express from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Morgan Stanley decreased their target price on shares of PetMed Express from $2.15 to $1.40 and set an “underweight” rating for the company in a research note on Friday, September 25th. Finally, Weiss Ratings lowered shares of PetMed Express from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 29th. Three investment analysts have rated the stock with a Sell rating. According to data from MarketBeat.com, PetMed Express presently has a consensus rating of “Strong Sell” and a consensus price target of $1.40.

PetMed Express Company Profile

PetMed Express, Inc is an online pet pharmacy and specialty retailer that markets pet medications, food, and healthcare products directly to consumers. The company operates under the 1-800-PetMeds brand and focuses primarily on products for dogs and cats.

Its product offerings include prescription and nonprescription medications, flea and tick treatments, heartworm preventives, supplements, and other veterinary health products. PetMed Express also sells pet food, treats, supplies, and select general wellness products through its digital platforms and customer service channels.

Founded in 1996, the company serves pet owners throughout the United States.